SlideShare a Scribd company logo
Lutein and Zeaxanthin Supplementation and
Association With Visual Function in Age-
Related Macular Degeneration
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553.
2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
Introduction
• Age-related macular degeneration (AMD) is a progressively degenerative
disease at the central area of the retina, which results in severe visual
impairment.
• It is the leading cause of irreversible blindness among people aged over 65 in
developed countries.
• With growing longevity, the number of AMD patients is likely to double in 2010
to 2050 in the United States, and this disease is becoming a crucial issue that
threatens public health in the aging population.Therefore, it is urgent to find
feasible interventions to decrease the visual impairment for AMD patients, and
ultimately reduce the burden of this disease.
• Although the exact pathogenesis of AMD remains incompletely understood,
light-initiated oxidative damage and the reduction of macular pigment (MP)
are hypothesized to be the putative mechanisms involved in the disease.
• The xanthophyll carotenoids, lutein (L) and zeaxanthin (Z), are concentrated
at the central fovea of the macula and compose the macular pigment. They are
believed to protect the macular region from photo-oxidative injury by
scavenging reactive oxygen species and filtering blue light, which indicates that
these carotenoids may play a role in improving visual function, especially for
AMD patients
From:JAMA Ophthalmol. 2013; 131: 564–572. ;Invest Ophthalmol Vis Sci. 2011; 52: 3934–3942
• Previous epidemiologic studies have shown that higher-level dietary intake of
L and Z was associated with decreased AMD risk and less visual
impairment.
From:Arch Ophthalmol. 2011; 129: 758–766.:AREDS Report No. 22. Arch Ophthalmol. 2007; 125: 1225–1232.
• Several intervention studies suggested that visual function of AMD patients was
improved by L or/and Z supplementation but others still failed to find such
results.
• Therefore, we conducted a meta-analysis of randomized controlled trials
(RCTs) to evaluate the visual performance in AMD with L and Z
supplementation.
Introduction
• Systematic literatures up to April 2014 on PubMed, EMBASE, Web of Science,
and Cochrane Library database were searched.
• Key word: Lutein (L), zeaxanthin (Z), xanthophyll, carotenoids and visual
function, visual performance, visual acuity (VA), vision, contrast sensitivity (CS),
glare sensitivity (GS), AMD, age-related maculopathy, neovascular AMD,
exudative AMD, choroidal neovascularization, and geographic atrophy
Study Selection
1. Only studies fulfilling the following criteria were included in the meta-
analysis: (1) eligible studies were limited to RCTs, (2) patients were
diagnosed as AMD and randomized to receive L or/and Z or placebo, and
(3) the outcome of interest was visual function variables, including VA, CS,
glare recovery time (GRT), and the score of Visual Function
Questionnaire (VFQ).
2. If multiple articles were published from the same study, only the last
published report was selected for analysis, and the previous could
be reviewed as supplementations for missing data where applicable.
Methods
Data Extraction and Study Quality Assessment:
- The study characteristics recorded were as followings: name of first author, year of publication,
duration of intervention, characteristics of patients (age, sex), the mean dosage of L or/and Z
supplements, outcome measurements, and corresponding assessment methods. For intervention and
placebo groups in each trial, information for the number of patients in each group, the mean and
corresponding SD 。
-The quality of each study included was assessed by the Jadad score, a 5-point study quality
assessment instrument and Studies that gained over a 3 Jadad score were considered to be
categorized as high quality.
Statistical Analysis
-The principal summary measures were the weighted mean differences (WMDs) and
corresponding 95% confidence intervals (CIs).
-The presence of statistically significant heterogeneity was evaluated by conducting Q tests; and
the extent of the observed heterogeneity was assessed by the I2 statistic.
-Sensitivity analyses were conducted to determine the robustness of our conclusions
-Stratified analyses were performed to explore the source of heterogeneity among variables,
Methods
• The search strategy yielded 496 citations in total. Among these citations, 441
were excluded after abstract review.
-The excluded studies contained duplicate publications, review articles, non-
RCTs, and studies without original human research.
-On more detailed evaluation, 47 citations were excluded for the following
reasons: duplicate publication, no outcomes suitable for the meta-analysis, lack of a
placebo group, no means or SDs included in the publication.
-The remaining eight studies met the inclusion criteria and were included in this
meta-analysis.
Result
Characteristics of the Eligible RCTs
Forest plot showing the efficacy of lutein and zeaxanthin
supplements on VA for patients with AMD.
logMAR
• The regression models showed
that a linear improvement in VA
was related to the increase in the
dosage of these carotenoids
supplement (r = −0.52, P = 0.03)
• In the dose-response meta-
analysis, each 1mg/day
increase in these carotenoids
supplementation was associated
with a 0.003 statistically
significant reduction in
logMAR levels.
Stratified Analysis for the
Lutein or/and Zeaxanthin
Supplements Effect on VA
across the Assessed
RCTs
• In the CS comparisons
between the intervention
groups and placebo
groups, significant
postintervention
increase was found at all
four spatial frequencies
(WMD ranging from 0.08–
0.18; all P < 0.05).
• The result of dose-
response analysis
showed that CS improved
0.010, 0.007, and 0.006 at
3, 6, and 12
cycles/degree
respectively, due to a
1mg/day increase in L
and Z supplement.
The Relationship Between the Change in MPOD
and Visual Outcomes
• Correlation analysis showed that VA was markedly improved with
the postintervention increase in MPOD (r = −0.58, P = 0.02).
• Additionally, CS at 12 cycles/degree was positively associated with
MPOD augmentation (r = 0.94, P < 0.001),
• Furthermore, the increment in MPOD was not related to the
postintervention decrease in GRT (P > 0.05).
Discussion
• Bian et al. indicated that incubation of the N-retinylidene-N-
retinylethanolamine (A2E)-containing RPE with L or Z could
significantly attenuate the photooxidation-induced
inactivation of the proteasome.
• Results from animal experiments showed that 6-month
supplementation with xanthophyll carotenoids in quails could
markedly decrease the level of photoreceptor apoptosis in
response to light injury.38
• The potential mechanism of action of these carotenoids was also
thought to involve in the reduction of chromatic aberration by
absorbing the blue light.
Discussion
First, there were relatively few studies included in this meta-analysis, which might
have limited power to detect statistical differences in the individual end points with L
or/and Z supplementation reliably.
• we examined the totality of the evidence by pooling the data from all available RCTs,
for the findings from these studies were less likely to be restricted compared with
observational studies
• All studies included were considered as high quality, which might enhance the
reliability of our finding.
Second, due to the relatively shorter intervention duration in most studies and the
lack of follow-up after intervention cessation, a question remained unanswered that
whether these carotenoids had long-term beneficial effects on visual function or not.
• Nevertheless, a significant effect on VA improvement after these carotenoids
supplementation was found in the present study. So it is promising that visual
function will be improved markedly by L and Z supplementation for AMD patients.
Conclusion
• This meta-analysis demonstrated significant benefits of L and Z
supplementation to VA and CS for AMD patients, which was positively
associated with MPOD elevation. However, as the relatively smaller number
of RCTs included may limit the power of this study, further large longer-
term RCTs are required to confirm the findings of this review, and to
determine the mechanism of association between supplementation status and
outcomes.
Thanks for your attention
視敏度(visual acuity)測量僅反映黃斑對高對比度、小目標的分辨功
能
視力分辨二維物體形狀和位置的能力
形狀、亮度周圍對比度和光波波長等的
• Third, majority of the studies were predominantly performed in Western
participants, and the generalizability of the meta-analyses might be
limited to a wider population.
• Fourth, our results might be affected by some potential confounding
factors, although the variables in all the researches incorporated had
been adjusted, and identified confounding in each study was also
effectively eliminated by randomly allocating patients.
• Finally, publication bias could not be ruled out completely even though
it was not detectable in the current analysis.
Discussion
Luitein and macular degenration
Luitein and macular degenration

More Related Content

What's hot

Aderenta si riscul cardiovascul
Aderenta si riscul cardiovasculAderenta si riscul cardiovascul
Aderenta si riscul cardiovascul
ALEXANDRU ANDRITOIU
 
Health of dentists in united arab emirates idj12000
Health of dentists in united arab emirates idj12000Health of dentists in united arab emirates idj12000
Health of dentists in united arab emirates idj12000Axex Dental
 
OIS 2014 Year in Review
OIS 2014 Year in ReviewOIS 2014 Year in Review
OIS 2014 Year in Review
Healthegy
 
Updates from AMD clinical trials
Updates from AMD clinical trialsUpdates from AMD clinical trials
Updates from AMD clinical trials
Yasuo Yanagi
 
Sle an update_lfa_20151007
Sle an update_lfa_20151007Sle an update_lfa_20151007
Sle an update_lfa_20151007
lupusdmv
 
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt PrasadTreatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
drsomduttprasad
 
Nw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment Options
Nawat Watanachai
 
Thriving, not just surviving after critical illness
Thriving, not just surviving after critical illnessThriving, not just surviving after critical illness
Thriving, not just surviving after critical illness
Coda Change
 
GP coverage of workers compensation in Australia
GP coverage of workers compensation in AustraliaGP coverage of workers compensation in Australia
GP coverage of workers compensation in Australia
Alex Collie
 
Tozal Webinar
Tozal WebinarTozal Webinar
Tozal Webinar
zia021
 
Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.
iosrjce
 
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
drsomduttprasad
 
CCHP Overview
CCHP OverviewCCHP Overview
CCHP Overview
andreacamden
 
Epstein Mmws
Epstein MmwsEpstein Mmws
Epstein Mmwsenforme
 
Increased prevalence of binocular visual disorders and optic neuropathy in ch...
Increased prevalence of binocular visual disorders and optic neuropathy in ch...Increased prevalence of binocular visual disorders and optic neuropathy in ch...
Increased prevalence of binocular visual disorders and optic neuropathy in ch...
Danielle Doppee
 
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...M. Christopher Roebuck
 
PRA Insights Report: Alzheimer's Disease Research
PRA Insights Report: Alzheimer's Disease ResearchPRA Insights Report: Alzheimer's Disease Research
PRA Insights Report: Alzheimer's Disease Research
Emma Whieldon
 
Age Related Macular Degeneration- Update with Case Studies
Age Related Macular Degeneration- Update with Case StudiesAge Related Macular Degeneration- Update with Case Studies
Age Related Macular Degeneration- Update with Case Studies
presmedaustralia
 

What's hot (19)

Aderenta si riscul cardiovascul
Aderenta si riscul cardiovasculAderenta si riscul cardiovascul
Aderenta si riscul cardiovascul
 
Health of dentists in united arab emirates idj12000
Health of dentists in united arab emirates idj12000Health of dentists in united arab emirates idj12000
Health of dentists in united arab emirates idj12000
 
OIS 2014 Year in Review
OIS 2014 Year in ReviewOIS 2014 Year in Review
OIS 2014 Year in Review
 
Updates from AMD clinical trials
Updates from AMD clinical trialsUpdates from AMD clinical trials
Updates from AMD clinical trials
 
Sle an update_lfa_20151007
Sle an update_lfa_20151007Sle an update_lfa_20151007
Sle an update_lfa_20151007
 
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt PrasadTreatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
 
Nw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment Options
 
Thriving, not just surviving after critical illness
Thriving, not just surviving after critical illnessThriving, not just surviving after critical illness
Thriving, not just surviving after critical illness
 
GP coverage of workers compensation in Australia
GP coverage of workers compensation in AustraliaGP coverage of workers compensation in Australia
GP coverage of workers compensation in Australia
 
Outcome in head injured patients indian experience
Outcome in head injured patients indian experienceOutcome in head injured patients indian experience
Outcome in head injured patients indian experience
 
Tozal Webinar
Tozal WebinarTozal Webinar
Tozal Webinar
 
Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.
 
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
Dr Somdutt Prasad on Current Management of DME: Learning from Protocol T2 Res...
 
CCHP Overview
CCHP OverviewCCHP Overview
CCHP Overview
 
Epstein Mmws
Epstein MmwsEpstein Mmws
Epstein Mmws
 
Increased prevalence of binocular visual disorders and optic neuropathy in ch...
Increased prevalence of binocular visual disorders and optic neuropathy in ch...Increased prevalence of binocular visual disorders and optic neuropathy in ch...
Increased prevalence of binocular visual disorders and optic neuropathy in ch...
 
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...
Value of Medication Adherence in Chronic Vascular Disease: Fixed Effects Mode...
 
PRA Insights Report: Alzheimer's Disease Research
PRA Insights Report: Alzheimer's Disease ResearchPRA Insights Report: Alzheimer's Disease Research
PRA Insights Report: Alzheimer's Disease Research
 
Age Related Macular Degeneration- Update with Case Studies
Age Related Macular Degeneration- Update with Case StudiesAge Related Macular Degeneration- Update with Case Studies
Age Related Macular Degeneration- Update with Case Studies
 

Viewers also liked

Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Advanced Cell Technology, Inc.
 
Presentazione food & nutrition forum ita
Presentazione food & nutrition forum itaPresentazione food & nutrition forum ita
Presentazione food & nutrition forum ita
Gianluca Tognon
 
Computer Vision Syndrome
Computer Vision SyndromeComputer Vision Syndrome
Computer Vision Syndrome
Dr. Jagannath Boramani
 
Computer Vision Syndrome
Computer Vision Syndrome Computer Vision Syndrome
Computer Vision Syndrome
Saji Salam MD,MBA
 
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
JASHU JASWANTH
 
Computer Vision Syndrome
Computer Vision SyndromeComputer Vision Syndrome
Computer Vision Syndrome
personalp
 

Viewers also liked (6)

Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
Presentation at World Stem Cell & Regenerative Medicine Congress, London. May...
 
Presentazione food & nutrition forum ita
Presentazione food & nutrition forum itaPresentazione food & nutrition forum ita
Presentazione food & nutrition forum ita
 
Computer Vision Syndrome
Computer Vision SyndromeComputer Vision Syndrome
Computer Vision Syndrome
 
Computer Vision Syndrome
Computer Vision Syndrome Computer Vision Syndrome
Computer Vision Syndrome
 
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
COMPUTER VISION SYNDROME( CVS ) with SOFTWARE LINK involved in it.
 
Computer Vision Syndrome
Computer Vision SyndromeComputer Vision Syndrome
Computer Vision Syndrome
 

Similar to Luitein and macular degenration

DME management
DME managementDME management
DME management
Devin Prabhakar
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptx
RashtriyaSamajseviPa
 
Important trials in Glaucoma
Important trials in GlaucomaImportant trials in Glaucoma
Important trials in Glaucoma
Laxmi Eye Institute
 
Ocular Hypertension
Ocular HypertensionOcular Hypertension
Ocular Hypertension
Dr Saurabh Kushwaha
 
Whats New in AMD - 2013
Whats New in AMD - 2013Whats New in AMD - 2013
Whats New in AMD - 2013
Rick Trevino
 
MedicalResearch.com: Medical Research Exclusive Interviews April 20 2015
MedicalResearch.com:  Medical Research Exclusive Interviews April 20  2015MedicalResearch.com:  Medical Research Exclusive Interviews April 20  2015
MedicalResearch.com: Medical Research Exclusive Interviews April 20 2015
Marie Benz MD FAAD
 
Schneider Alzforum webinar may2015
Schneider  Alzforum webinar may2015Schneider  Alzforum webinar may2015
Schneider Alzforum webinar may2015
Alzforum
 
Health Care Systems Policy.docx
Health Care Systems Policy.docxHealth Care Systems Policy.docx
Health Care Systems Policy.docx
write12
 
Health Care Systems Policy.docx
Health Care Systems Policy.docxHealth Care Systems Policy.docx
Health Care Systems Policy.docx
write4
 
Role of Biomarkers in Alzheimers Disease
Role of Biomarkers in Alzheimers DiseaseRole of Biomarkers in Alzheimers Disease
Role of Biomarkers in Alzheimers Disease
Pramod Krishnan
 
ARVO 2013 Chor 4-27-2013
ARVO 2013 Chor 4-27-2013ARVO 2013 Chor 4-27-2013
ARVO 2013 Chor 4-27-2013Eric Chen
 
RCT.pptx
RCT.pptxRCT.pptx
RCT.pptx
Kritika Sarkar
 
Diabetic macular edema studies
Diabetic macular edema studiesDiabetic macular edema studies
Diabetic macular edema studies
abubaker77
 
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
Alexander Decker
 
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGISTDiabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
AjayDudani1
 
Iop compliance and fluctuations
Iop compliance and fluctuationsIop compliance and fluctuations
Iop compliance and fluctuations
Michael Duplessie
 
Management of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicineManagement of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicine
Hind Safwat
 
The new treatment paradigm for MS
The new treatment paradigm for MSThe new treatment paradigm for MS
The new treatment paradigm for MS
MS Trust
 
Diabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalezDiabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalez
Diopsys, Inc.
 

Similar to Luitein and macular degenration (20)

DME management
DME managementDME management
DME management
 
Ocular Hypertension Treatment study (OHTS).pptx
Ocular Hypertension Treatment  study (OHTS).pptxOcular Hypertension Treatment  study (OHTS).pptx
Ocular Hypertension Treatment study (OHTS).pptx
 
Important trials in Glaucoma
Important trials in GlaucomaImportant trials in Glaucoma
Important trials in Glaucoma
 
Ocular Hypertension
Ocular HypertensionOcular Hypertension
Ocular Hypertension
 
Whats New in AMD - 2013
Whats New in AMD - 2013Whats New in AMD - 2013
Whats New in AMD - 2013
 
MedicalResearch.com: Medical Research Exclusive Interviews April 20 2015
MedicalResearch.com:  Medical Research Exclusive Interviews April 20  2015MedicalResearch.com:  Medical Research Exclusive Interviews April 20  2015
MedicalResearch.com: Medical Research Exclusive Interviews April 20 2015
 
Schneider Alzforum webinar may2015
Schneider  Alzforum webinar may2015Schneider  Alzforum webinar may2015
Schneider Alzforum webinar may2015
 
Health Care Systems Policy.docx
Health Care Systems Policy.docxHealth Care Systems Policy.docx
Health Care Systems Policy.docx
 
Health Care Systems Policy.docx
Health Care Systems Policy.docxHealth Care Systems Policy.docx
Health Care Systems Policy.docx
 
Role of Biomarkers in Alzheimers Disease
Role of Biomarkers in Alzheimers DiseaseRole of Biomarkers in Alzheimers Disease
Role of Biomarkers in Alzheimers Disease
 
ARVO 2013 Chor 4-27-2013
ARVO 2013 Chor 4-27-2013ARVO 2013 Chor 4-27-2013
ARVO 2013 Chor 4-27-2013
 
RCT.pptx
RCT.pptxRCT.pptx
RCT.pptx
 
Diabetic macular edema studies
Diabetic macular edema studiesDiabetic macular edema studies
Diabetic macular edema studies
 
DISCUSSION KVN.pptx
DISCUSSION KVN.pptxDISCUSSION KVN.pptx
DISCUSSION KVN.pptx
 
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
Effect of rosuvastatin on rheumatoid arthritis clinical disease activity inde...
 
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGISTDiabetic retinopathy for GENERAL OPHTHALMOLOGIST
Diabetic retinopathy for GENERAL OPHTHALMOLOGIST
 
Iop compliance and fluctuations
Iop compliance and fluctuationsIop compliance and fluctuations
Iop compliance and fluctuations
 
Management of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicineManagement of early glaucoma: Evidence based medicine
Management of early glaucoma: Evidence based medicine
 
The new treatment paradigm for MS
The new treatment paradigm for MSThe new treatment paradigm for MS
The new treatment paradigm for MS
 
Diabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalezDiabetic retinopathy management an advanced approach gonzalez
Diabetic retinopathy management an advanced approach gonzalez
 

Recently uploaded

ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
rowala30
 
Feeding plate for a newborn with Cleft Palate.pptx
Feeding plate for a newborn with Cleft Palate.pptxFeeding plate for a newborn with Cleft Palate.pptx
Feeding plate for a newborn with Cleft Palate.pptx
SatvikaPrasad
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Guillermo Rivera
 
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyDr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
R3 Stem Cell
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Sankalpa Gunathilaka
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
Naeemshahzad51
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
The Lifesciences Magazine
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Dr. David Greene Arizona
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
Rommel Luis III Israel
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
AbdulMunim54
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
eurohealthleaders
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
nktiacc3
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
SGRT Community
 
Top massage center in ajman chandrima Spa
Top massage center in ajman chandrima  SpaTop massage center in ajman chandrima  Spa
Top massage center in ajman chandrima Spa
Chandrima Spa Ajman
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
DIVYANSHU740006
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
Dr Rachana Gujar
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Health Catalyst
 
PET CT beginners Guide covers some of the underrepresented topics in PET CT
PET CT  beginners Guide  covers some of the underrepresented topics  in PET CTPET CT  beginners Guide  covers some of the underrepresented topics  in PET CT
PET CT beginners Guide covers some of the underrepresented topics in PET CT
MiadAlsulami
 
Trauma Outpatient Center .
Trauma Outpatient Center                       .Trauma Outpatient Center                       .
Trauma Outpatient Center .
TraumaOutpatientCent
 

Recently uploaded (20)

ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
ALKAMAGIC PLAN 1350.pdf plan based of door to door delivery of alkaline water...
 
Feeding plate for a newborn with Cleft Palate.pptx
Feeding plate for a newborn with Cleft Palate.pptxFeeding plate for a newborn with Cleft Palate.pptx
Feeding plate for a newborn with Cleft Palate.pptx
 
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...
 
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyDr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in Cardiology
 
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsxChild Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
Child Welfare Clinic and Well baby clinicin Sri Lanka.ppsx
 
Dimensions of Healthcare Quality
Dimensions of Healthcare QualityDimensions of Healthcare Quality
Dimensions of Healthcare Quality
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
 
ABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROMEABDOMINAL COMPARTMENT SYSNDROME
ABDOMINAL COMPARTMENT SYSNDROME
 
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhfOne Gene One Enzyme Theory.pptxvhvhfhfhfhf
One Gene One Enzyme Theory.pptxvhvhfhfhfhf
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
 
The positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experienceThe positive impact of SGRT – The Berkshire Cancer Centre experience
The positive impact of SGRT – The Berkshire Cancer Centre experience
 
Top massage center in ajman chandrima Spa
Top massage center in ajman chandrima  SpaTop massage center in ajman chandrima  Spa
Top massage center in ajman chandrima Spa
 
Professional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine LectureProfessional Secrecy: Forensic Medicine Lecture
Professional Secrecy: Forensic Medicine Lecture
 
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
 
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondEmpowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
Empowering ACOs: Leveraging Quality Management Tools for MIPS and Beyond
 
PET CT beginners Guide covers some of the underrepresented topics in PET CT
PET CT  beginners Guide  covers some of the underrepresented topics  in PET CTPET CT  beginners Guide  covers some of the underrepresented topics  in PET CT
PET CT beginners Guide covers some of the underrepresented topics in PET CT
 
Trauma Outpatient Center .
Trauma Outpatient Center                       .Trauma Outpatient Center                       .
Trauma Outpatient Center .
 

Luitein and macular degenration

  • 1. Lutein and Zeaxanthin Supplementation and Association With Visual Function in Age- Related Macular Degeneration Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553. 2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
  • 2. Introduction • Age-related macular degeneration (AMD) is a progressively degenerative disease at the central area of the retina, which results in severe visual impairment. • It is the leading cause of irreversible blindness among people aged over 65 in developed countries. • With growing longevity, the number of AMD patients is likely to double in 2010 to 2050 in the United States, and this disease is becoming a crucial issue that threatens public health in the aging population.Therefore, it is urgent to find feasible interventions to decrease the visual impairment for AMD patients, and ultimately reduce the burden of this disease. • Although the exact pathogenesis of AMD remains incompletely understood, light-initiated oxidative damage and the reduction of macular pigment (MP) are hypothesized to be the putative mechanisms involved in the disease.
  • 3. • The xanthophyll carotenoids, lutein (L) and zeaxanthin (Z), are concentrated at the central fovea of the macula and compose the macular pigment. They are believed to protect the macular region from photo-oxidative injury by scavenging reactive oxygen species and filtering blue light, which indicates that these carotenoids may play a role in improving visual function, especially for AMD patients From:JAMA Ophthalmol. 2013; 131: 564–572. ;Invest Ophthalmol Vis Sci. 2011; 52: 3934–3942 • Previous epidemiologic studies have shown that higher-level dietary intake of L and Z was associated with decreased AMD risk and less visual impairment. From:Arch Ophthalmol. 2011; 129: 758–766.:AREDS Report No. 22. Arch Ophthalmol. 2007; 125: 1225–1232. • Several intervention studies suggested that visual function of AMD patients was improved by L or/and Z supplementation but others still failed to find such results. • Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the visual performance in AMD with L and Z supplementation. Introduction
  • 4. • Systematic literatures up to April 2014 on PubMed, EMBASE, Web of Science, and Cochrane Library database were searched. • Key word: Lutein (L), zeaxanthin (Z), xanthophyll, carotenoids and visual function, visual performance, visual acuity (VA), vision, contrast sensitivity (CS), glare sensitivity (GS), AMD, age-related maculopathy, neovascular AMD, exudative AMD, choroidal neovascularization, and geographic atrophy Study Selection 1. Only studies fulfilling the following criteria were included in the meta- analysis: (1) eligible studies were limited to RCTs, (2) patients were diagnosed as AMD and randomized to receive L or/and Z or placebo, and (3) the outcome of interest was visual function variables, including VA, CS, glare recovery time (GRT), and the score of Visual Function Questionnaire (VFQ). 2. If multiple articles were published from the same study, only the last published report was selected for analysis, and the previous could be reviewed as supplementations for missing data where applicable. Methods
  • 5. Data Extraction and Study Quality Assessment: - The study characteristics recorded were as followings: name of first author, year of publication, duration of intervention, characteristics of patients (age, sex), the mean dosage of L or/and Z supplements, outcome measurements, and corresponding assessment methods. For intervention and placebo groups in each trial, information for the number of patients in each group, the mean and corresponding SD 。 -The quality of each study included was assessed by the Jadad score, a 5-point study quality assessment instrument and Studies that gained over a 3 Jadad score were considered to be categorized as high quality. Statistical Analysis -The principal summary measures were the weighted mean differences (WMDs) and corresponding 95% confidence intervals (CIs). -The presence of statistically significant heterogeneity was evaluated by conducting Q tests; and the extent of the observed heterogeneity was assessed by the I2 statistic. -Sensitivity analyses were conducted to determine the robustness of our conclusions -Stratified analyses were performed to explore the source of heterogeneity among variables, Methods
  • 6. • The search strategy yielded 496 citations in total. Among these citations, 441 were excluded after abstract review. -The excluded studies contained duplicate publications, review articles, non- RCTs, and studies without original human research. -On more detailed evaluation, 47 citations were excluded for the following reasons: duplicate publication, no outcomes suitable for the meta-analysis, lack of a placebo group, no means or SDs included in the publication. -The remaining eight studies met the inclusion criteria and were included in this meta-analysis. Result
  • 7. Characteristics of the Eligible RCTs
  • 8. Forest plot showing the efficacy of lutein and zeaxanthin supplements on VA for patients with AMD. logMAR
  • 9. • The regression models showed that a linear improvement in VA was related to the increase in the dosage of these carotenoids supplement (r = −0.52, P = 0.03) • In the dose-response meta- analysis, each 1mg/day increase in these carotenoids supplementation was associated with a 0.003 statistically significant reduction in logMAR levels.
  • 10. Stratified Analysis for the Lutein or/and Zeaxanthin Supplements Effect on VA across the Assessed RCTs
  • 11. • In the CS comparisons between the intervention groups and placebo groups, significant postintervention increase was found at all four spatial frequencies (WMD ranging from 0.08– 0.18; all P < 0.05). • The result of dose- response analysis showed that CS improved 0.010, 0.007, and 0.006 at 3, 6, and 12 cycles/degree respectively, due to a 1mg/day increase in L and Z supplement.
  • 12.
  • 13. The Relationship Between the Change in MPOD and Visual Outcomes • Correlation analysis showed that VA was markedly improved with the postintervention increase in MPOD (r = −0.58, P = 0.02). • Additionally, CS at 12 cycles/degree was positively associated with MPOD augmentation (r = 0.94, P < 0.001), • Furthermore, the increment in MPOD was not related to the postintervention decrease in GRT (P > 0.05).
  • 14. Discussion • Bian et al. indicated that incubation of the N-retinylidene-N- retinylethanolamine (A2E)-containing RPE with L or Z could significantly attenuate the photooxidation-induced inactivation of the proteasome. • Results from animal experiments showed that 6-month supplementation with xanthophyll carotenoids in quails could markedly decrease the level of photoreceptor apoptosis in response to light injury.38 • The potential mechanism of action of these carotenoids was also thought to involve in the reduction of chromatic aberration by absorbing the blue light.
  • 15. Discussion First, there were relatively few studies included in this meta-analysis, which might have limited power to detect statistical differences in the individual end points with L or/and Z supplementation reliably. • we examined the totality of the evidence by pooling the data from all available RCTs, for the findings from these studies were less likely to be restricted compared with observational studies • All studies included were considered as high quality, which might enhance the reliability of our finding. Second, due to the relatively shorter intervention duration in most studies and the lack of follow-up after intervention cessation, a question remained unanswered that whether these carotenoids had long-term beneficial effects on visual function or not. • Nevertheless, a significant effect on VA improvement after these carotenoids supplementation was found in the present study. So it is promising that visual function will be improved markedly by L and Z supplementation for AMD patients.
  • 16. Conclusion • This meta-analysis demonstrated significant benefits of L and Z supplementation to VA and CS for AMD patients, which was positively associated with MPOD elevation. However, as the relatively smaller number of RCTs included may limit the power of this study, further large longer- term RCTs are required to confirm the findings of this review, and to determine the mechanism of association between supplementation status and outcomes.
  • 17. Thanks for your attention
  • 19. • Third, majority of the studies were predominantly performed in Western participants, and the generalizability of the meta-analyses might be limited to a wider population. • Fourth, our results might be affected by some potential confounding factors, although the variables in all the researches incorporated had been adjusted, and identified confounding in each study was also effectively eliminated by randomly allocating patients. • Finally, publication bias could not be ruled out completely even though it was not detectable in the current analysis. Discussion